The laboratory is primarily focused on vaccine development as well as understanding the pathogenesis of emerging and re-emerging mosquito-borne RNA viruses and SARS-CoV-2 in animal and human cell culture models. 1. Adam A, Luo H, Osman S, B Wang, C Roundy, AJ Auguste, Plante KS.,BH Peng, S Thangamani, EI Frolova, I Frolov, Weaver S, and Wang T. Optimized production and immunogenicity of an insect virus- based chikungunya virus candidate vaccine in cell culture and animal models. Emerg Microbes Infect. 2021 Feb 4:1-33. 2. Adam A, Shi Q, Wang B, Zou J, Mai J, Osman SR, Wu W, Xie X, Aguilar PV, Bao X, Shi PY, Shen H, Wang T. 2022. A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. Transl Res. 2022 Jun 8. 3. Luo H, G Li, B Wang, B Tian, J Gao, Zou J, S Shi, Zhu S, BH Peng, Adam A, A Martinez, K Hein, ER Winkelman, Y Mahmoud, Zhou X, C Shan, S Rossi, S Weaver, ADT Barrett, SC Sun, W Zhang, PY Shi, P Wu, and Wang T. 2020. Peli1 signaling blockade attenuates congenital zika syndrome. PLoS Pathog. 16(6):e1008538.
Employee medical insurance included.
Current Job Openings